HOME >> BIOLOGY >> NEWS
Less intense response to alcohol sheds light on genetic tracing of alcohol dependence

NEW YORK--Clues looking into the root causes of alcoholism are emerging from new findings that center on the genetic patterns of young drinkers, with particular focus on why adolescents are more likely to drink large quantities of alcohol even if they need more alcohol to get the effects they desire.

"The study offers a unique perspective on the beginnings of the alcohol experience and usage patterns of 12-year-olds," explained principal investigator Marc Schuckit, M.D., professor of psychiatry at the Veterans Affairs San Diego Healthcare System. "This is the first study correlating the intensity of reaction to alcohol with the amount of alcohol consumed at an early age."

Dr. Schuckit, who also is distinguished professor of psychiatry at the University of California, San Diego Medical School, spoke today at the American Medical Association media briefing, Alcohol Dependence: From Science to Solutions, held in New York City. He also released his study "Performance of a self-reported measure of the level of response to alcohol in 12- to 13-year-olds" published in the July issue of The Journal of Studies on Alcohol.

In the study, 80 children in Bristol, England, who had some experience with alcohol responded to a questionnaire regarding their drinking habits. On average, the respondents reported drinking alcohol about five times in the previous six months. While most of them only consumed one or two drinks at a time, a significant number reported having four to six drinks at a time.

A low response to alcohol is a risk factor for alcohol dependence and a predictor of future alcoholism. "When children with a family history of alcohol dependence begin drinking, about half of them experience little or no intoxication at blood alcohol levels where others would be feeling moderately tipsy," said Dr. Schuckit. "Consequently, these adolescents have a propensity to drink more heavily when they drink because higher blood alcohol levels are
'"/>

Contact: Marc Schuckit, M.D.
858-552-8585 x7978
American Medical Association
21-Jul-2005


Page: 1 2 3

Related biology news :

1. New gene marker may identify need for intense AML therapy
2. MIT model could predict cells response to drugs
3. Strength of connections between brain regions may affect an adolescents response to peer influence
4. A friendly foe -- Bacteria residing in the gut boost immune response to tumors
5. Identified main genetic variants involved in response to HIV
6. Minister Lunn announces $39.6M for next phase of mountain pine beetle response
7. Columbine flowers develop long nectar spurs in response to pollinators
8. PET accurately identifies esophageal cancer patients positive responses to chemotherapy
9. Every moment counts: Predicting treatment responses earlier for brain tumor patients
10. FDG-PET imaging clearly predicts lung cancer patients response to chemotherapy
11. Study shows response to financial loss parallels brains processing of pain

Post Your Comments:
(Date:12/17/2014)... -- Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ... with the clinical data to back it up," said ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
(Date:12/10/2014)... Dec. 9, 2014  Wake Forest Baptist Medical Center today ... its School of Medicine. Funding for this $50 million ... that will be publicly launched next summer. ... the former 60 series R.J. Reynolds Tobacco Company complex, ... will begin immediately with plans to be ready to ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
(Date:12/19/2014)... The empty capsules market is experiencing growth ... technological innovations in the empty capsules market. The ... growth of the empty capsules market. , Get ... of Report , The report will enrich both ... to gauge the pulse of the market which ...
(Date:12/19/2014)... YORK , Dec. 18, 2014 Relmada ... therapies for the treatment of chronic pain, announced the ... today. "This was a transformational year in ... promising future for our company," said Sergio Traversa ... year, we have executed on key financial, human resource ...
(Date:12/17/2014)... December 17, 2014 Ipsen Biopharmaceuticals, ... IPN; ADR: IPSEY), today announced that ... as Somatuline®) was approved by the U.S. Food ... gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with ... metastatic disease to improve progression-free survival (PFS). , ...
(Date:12/17/2014)... Audacity, a leading California-based health and science ... Huntsworth Health Group, is proud to announce the addition ... role, Gonzales will serve as Senior Vice President of ... welcome a talent of Jamie’s caliber to the Audacity ... is a proven healthcare innovation leader and brand management ...
Breaking Biology Technology:Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2
Cached News: